These studies echo our findings in both breast (Figure 2(a)) and ovarian (Figure 2(b)) cancer patients harboring germline BRCA1/2m, as well as in our analysis of breast and ovarian cancer patients with BRCA1m or BRCA2m alone, helping to validate our meta-analysis results across cancer types. This evidence concerns the gene BRCA1 and ovarian cancer.